ArticleJournal of immunology (Baltimore, Md. : 1950)2008
TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation.
Article in Journal of immunology (Baltimore, Md. : 1950), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- The Use of the Humanized Mouse Model in Gene Therapy and Immunotherapy for HIV and Cancer.Frontiers in immunology · 2018Review
- Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model.Oncotarget · 2016Article
- Whole-body irradiation increases the magnitude and persistence of adoptively transferred T cells associated with tumor regression in a mouse model of prostate cancer.Cancer immunology research · 2014Article
- Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.American journal of blood research · 2014Review
- Tumor-targeting vaccination instructs graft-vs.-tumor immune responses.Oncoimmunology · 2013Article
- Gene-engineered T cells for cancer therapy.Nature reviews. Cancer · 2013Review
- T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term.Gene therapy · 2013Article
- Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.Frontiers in immunology · 2013Review
- Skin-resident antigen-presenting cells: instruction manual for vaccine development.Frontiers in immunology · 2013Article
- Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Evaluation of Epstein-Barr virus latent membrane protein 2 specific T-cell receptors driven by T-cell specific promoters using lentiviral vector.Clinical & developmental immunology · 2011Article
- Therapeutic cancer vaccines: are we there yet?Immunological reviews · 2011Review
- Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy.Archivum immunologiae et therapiae experimentalis · 2010Review
- Cancer immunotherapy: in vivo imaging of adoptively transferred T cells in an immunocompetent host.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.Nature medicine · 2010Article
- T cell receptor gene therapy for cancer.Human gene therapy · 2009Review
- TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.Cancer immunology, immunotherapy : CII · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
Analogous to the clinical use of recombinant high-affinity Abs, transfer of TCR genes may be used to create a T cell compartment specific for self-Ags to which the endogenous T cell repertoire is immune tolerant. In this study, we show in a spontaneous prostate carcinoma model that the combination of vaccination with adoptive transfer of small numbers of T cells that are genetically modified with a tumor-specific TCR results in a marked suppression of tumor development, even though both treatments are by themselves without effect. These results demonstrate the value of TCR gene transfer to target otherwise nonimmunogenic tumor-associated self-Ags provided that adoptive transfer occurs under conditions that allow in vivo expansion of the TCR-modified T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.